NASDAQ:FEMY

Femasys Q3 2026 Earnings Results & Report

Femasys logo
$1.12 -0.16 (-12.50%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 +0.02 (+1.79%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.53 versus the -$0.6050 consensus estimate, while revenue of $404.60 thousand fell short of the $620 thousand estimate by $215.40 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Femasys EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.6050
Beat/Miss
Beat by +$0.0750
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Femasys Revenue Results

Actual Revenue
$404.60 thousand
Expected Revenue
$620 thousand
Beat/Miss
Missed by -$215.40 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Femasys' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 20, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Femasys Q3 2026 Earnings FAQ

Femasys (NASDAQ:FEMY) reported earnings of -$0.53 per share for Q3 2026, beating the consensus estimate of -$0.6050. The report was announced on Friday, November 13, 2026.

Femasys reported revenue of $404.60 thousand for Q3 2026, against a consensus estimate of $620 thousand.

Femasys' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Femasys on the company's earnings history page.

Femasys Earnings Headlines

Femasys (NASDAQ:FEMY) Stock Rating Upgraded by Wall Street Zen
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.tc pixel
Femasys (NASDAQ:FEMY) Cut to Strong Sell at Wall Street Zen
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY) is a medical technology company focused on developing and commercializing products for women’s health, with an emphasis on fertility and contraception. Founded in 2004 and headquartered in Georgia, the company aims to provide minimally invasive options for reproductive care.

Its products include FemVue, a system used with ultrasound to evaluate whether a woman’s fallopian tubes are open, and FemaSeed, a device designed to deliver sperm closer to the site of fertilization during insemination. Femasys is also developing FemBloc, a non-surgical approach to permanent contraception.

Founder Kathy Lee-Sepsick serves as the company’s chief executive officer. Femasys is based in the United States and has pursued commercial and regulatory opportunities in domestic and international markets.

View Femasys Profile